Recent News

• 05.13.2025 - Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update
• 05.13.2025 - Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update
• 04.28.2025 - Evoke Pharma to Present New Data Comparing Tardive Dyskinesia Incidence in Continuous vs Intermittent Metoclopramide Use at DDW 2025
• 03.13.2025 - Evoke Pharma Fourth Quarter and Full Year 2024 Earnings
• 03.13.2025 - Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
• 03.13.2025 - Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
• 03.06.2025 - Evoke Pharma to Report Fourth Quarter and Full Year 2024 Results on March 13, 2025
• 02.24.2025 - Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors

Recent Filings

• 04.10.2025 - ARS Annual Report to Security Holders
• 04.10.2025 - DEF 14A Other definitive proxy statements
• 04.10.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 03.24.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 03.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.21.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 03.13.2025 - EX-99.1 EX-99.1
• 03.13.2025 - 8-K Current report
• 03.13.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]